188 related articles for article (PubMed ID: 19433856)
1. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
Assouline S; Culjkovic B; Cocolakis E; Rousseau C; Beslu N; Amri A; Caplan S; Leber B; Roy DC; Miller WH; Borden KL
Blood; 2009 Jul; 114(2):257-60. PubMed ID: 19433856
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine.
Assouline S; Gasiorek J; Bergeron J; Lambert C; Culjkovic-Kraljacic B; Cocolakis E; Zakaria C; Szlachtycz D; Yee K; Borden KLB
Haematologica; 2023 Nov; 108(11):2946-2958. PubMed ID: 36951168
[TBL] [Abstract][Full Text] [Related]
3. Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity.
Chen J; Xu X; Chen J
Biochem Biophys Res Commun; 2018 Nov; 506(3):604-610. PubMed ID: 30454696
[TBL] [Abstract][Full Text] [Related]
4. Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
Borden KL; Culjkovic-Kraljacic B
Leuk Lymphoma; 2010 Oct; 51(10):1805-15. PubMed ID: 20629523
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S; Culjkovic-Kraljacic B; Bergeron J; Caplan S; Cocolakis E; Lambert C; Lau CJ; Zahreddine HA; Miller WH; Borden KL
Haematologica; 2015 Jan; 100(1):e7-9. PubMed ID: 25425688
[No Abstract] [Full Text] [Related]
6. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.
Culjkovic-Kraljacic B; Fernando TM; Marullo R; Calvo-Vidal N; Verma A; Yang S; Tabbò F; Gaudiano M; Zahreddine H; Goldstein RL; Patel J; Taldone T; Chiosis G; Ladetto M; Ghione P; Machiorlatti R; Elemento O; Inghirami G; Melnick A; Borden KL; Cerchietti L
Blood; 2016 Feb; 127(7):858-68. PubMed ID: 26603836
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches.
Martínez A; Sesé M; Losa JH; Robichaud N; Sonenberg N; Aasen T; Ramón Y Cajal S
PLoS One; 2015; 10(4):e0123352. PubMed ID: 25923732
[TBL] [Abstract][Full Text] [Related]
8. The oncogene eIF4E: using biochemical insights to target cancer.
Carroll M; Borden KL
J Interferon Cytokine Res; 2013 May; 33(5):227-38. PubMed ID: 23472659
[TBL] [Abstract][Full Text] [Related]
9. Protein translation: biological processes and therapeutic strategies for human diseases.
Jia X; He X; Huang C; Li J; Dong Z; Liu K
Signal Transduct Target Ther; 2024 Feb; 9(1):44. PubMed ID: 38388452
[TBL] [Abstract][Full Text] [Related]
10. M7G-related tumor immunity: novel insights of RNA modification and potential therapeutic targets.
Han M; Huang Q; Li X; Chen X; Zhu H; Pan Y; Zhang B
Int J Biol Sci; 2024; 20(4):1238-1255. PubMed ID: 38385078
[TBL] [Abstract][Full Text] [Related]
11. Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in Cells.
Osborne MJ; Sulekha A; Culjkovic-Kraljacic B; Gasiorek J; Ruediger E; Jolicouer E; Marinier A; Assouline S; Borden KLB
J Mol Biol; 2024 Jan; 436(2):168378. PubMed ID: 38043731
[TBL] [Abstract][Full Text] [Related]
12. Comparison of anti-cancer effects of platinum ribavirin and ribavirin via telomerase and Bcl-2 gene expression.
Sabokrouh A; Hajivand S; Atabi F
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3907-3915. PubMed ID: 37975929
[TBL] [Abstract][Full Text] [Related]
13. The eukaryotic translation initiation factor eIF4E unexpectedly acts in splicing thereby coupling mRNA processing with translation: eIF4E induces widescale splicing reprogramming providing system-wide connectivity between splicing, nuclear mRNA export and translation.
Borden KLB
Bioessays; 2024 Jan; 46(1):e2300145. PubMed ID: 37926700
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Eukaryotic Initiating Factor eIF4E Overcomes Abemaciclib Resistance in Gastric Cancer.
Zha HL; Chen W; Shi W; Liao YY
Curr Med Sci; 2023 Oct; 43(5):927-934. PubMed ID: 37752406
[TBL] [Abstract][Full Text] [Related]
15. Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.
Mohi-Ud-Din R; Chawla A; Sharma P; Mir PA; Potoo FH; Reiner Ž; Reiner I; Ateşşahin DA; Sharifi-Rad J; Mir RH; Calina D
Eur J Med Res; 2023 Sep; 28(1):345. PubMed ID: 37710280
[TBL] [Abstract][Full Text] [Related]
16. Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment.
Takahashi S
Hematol Rep; 2023 May; 15(2):331-346. PubMed ID: 37367084
[TBL] [Abstract][Full Text] [Related]
17. Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer.
Fernandez A; Monsen PJ; Platanias LC; Schiltz GE
RSC Med Chem; 2023 Jun; 14(6):1060-1087. PubMed ID: 37360400
[TBL] [Abstract][Full Text] [Related]
18. N7-methylguanosine modification: from regulatory roles to therapeutic implications in cancer.
Cai M; Yang C; Wang Z
Am J Cancer Res; 2023; 13(5):1640-1655. PubMed ID: 37293166
[TBL] [Abstract][Full Text] [Related]
19. A novel approach to overcome drug resistance in acute myeloid leukemia.
Mazewski C; Platanias LC
Haematologica; 2023 Nov; 108(11):2889-2890. PubMed ID: 37165841
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
